IBT receives a further SEK 35 million funding from BioGaia

To support Infant Bacterial Therapeutics efforts to develop a drug to prevent the fatal disease necrotizing enterocolitis, BioGaia’s board of directors has resolved to invest a further SEK 35 million in IBT.

Read the official IBT press release here
Read the official BioGaia press release here

September 7, 2015